ASCO: As FDA’s Zolbetuximab Decision Looms, Astellas Looks To Meet Testing Challenge
Executive Summary
Scrip sat down with Astellas chief medical officer Tadaaki Taniguchi to talk about the drug maker’s plans for taking its Claudin18.2-targeting drug to the US market.